AbbVie Inc (ABBV)

pos +0.00
Today's Range: 0.00 - 0.00 | ABBV Avg Daily Volume: 6,798,700
Last Update: 04/23/14 - 4:01 PM EDT
Volume: 0
YTD Performance: -5.06%
Open: $0.00
Previous Close: $50.14
52 Week Range: $40.10 - $54.78
Oustanding Shares: 1,588,518,764
Market Cap: 79,818,469,352
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 3 4 4
Moderate Buy 0 0 0 0
Hold 5 5 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.11 2.25 2.11 2.20
Latest Dividend: 0.42
Latest Dividend Yield: 3.16%
Dividend Ex-Date: 04/11/14
Price Earnings Ratio: 20.74
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
20.74 10.80 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.60% 11.08% 0.00%
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
Revenue 18.38B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.68 $0.76 $3.12 $3.65
Number of Analysts 8 6 11 9
High Estimate $0.71 $0.81 $3.18 $3.93
Low Estimate $0.66 $0.72 $3.08 $3.40
Prior Year $0.68 $0.82 $3.14 $3.12
Growth Rate (Year over Year) 0.00% -7.11% -0.75% 16.98%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Its potent hepatitis C treatment is not a boon for shareholders.

Dividend D-Day Coming Real Money Pro($)

The goal is always simply to get out where we got in.
Mar 19, 2014 | 7:33 AM EDT
ABBV cut its number, Jefferies said. Competitive data in Hep C, pay for delay litigation re Androgel. $60 price target. 
Dec 19, 2013 | 7:48 AM EST
ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $57 price target. 
Dec 03, 2013 | 8:11 AM EST
ABBV was placed on the Conviction Buy list, according to Goldman Sachs. Company has an attractive pipeline, with multiple potential cat...
Oct 28, 2013 | 8:05 AM EDT
ABBV was upgraded from Market Perform to Outperform, BMO Capital said. $55 price target. Humira can drive impressive growth over the co...
Here's what Glen Dubin's Highbridge funds have been buying.
They can spend a lot of time analyzing their picks.
Jul 29, 2013 | 8:18 AM EDT
ABBV estimates were boosted through 2014, BMO Capital said. Company's pipeline is advancing and guidance appears beatable. Market Perfo...

Off the Charts Real Money Pro($)

Maintain a long-side bias until composure changes.

Columnist Conversations

I will have energy/electricity expert and fellow contributor Glenn Williams joining me after the close to talk...
As expected, offshore drilling firm Diamond Offshore (DO) declared their normal 12.5-cent quarterly payout + a...
Apple was off $6.95 (1.31%) in regular trading but is up over $37 (~7%) in the after markets, after announcing...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.